Invokamet Approval History

  • FDA approved: Yes (First approved August 8th, 2014)
  • Brand name: Invokamet
  • Generic name: canagliflozin and metformin
  • Company: Janssen Research & Development, LLC
  • Treatment for: Diabetes, Type 2

Invokamet (canagliflozin/metformin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.

FDA Approval History for Invokamet

DateArticle
Aug 11, 2014Approval FDA Approves Invokamet (canagliflozin/metformin) for Type 2 Diabetes
Dec 12, 2013FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes
Dec 12, 2012Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)